Table 1.

Uveal melanoma adjuvant therapy: randomized trials

Treatment	n	Treatment eligibility	Result	Reference
BCG i.d. weekly, 4 times; then monthly for 11 months	113	posterior uveal melanoma	no difference in survival rate of treated (59%, n = 34) vs. observation (70%, n = 79); p = 0.60	McLean et al. [6], 1990
Dacarbazine 200 mg/m2 i.v. daily for 5 days every 4 weeks, 6 times	348	>10 mm LTD, >5 mm tumor height	no difference in 5-year survival rate of treated (71%) vs. observation (68%); p = not significant	Desjardins et al. [5], 1998

i.d. = Intradermally; i.v. = intravenously; LTD = largest tumor diameter.